Engflag

Aq-10

Quick links to important sections

Aq-10

Aq-10_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aq-10

Aq-10 is formally classified as a Poly-nutrient supplement and a multicomponent supplement intended for systemic nutritional augmentation. The final preparation is presented as an oral capsule (softgel), facilitating oral absorption. It is best defined as a Nutraceutical with a physiological profile that supports Antioxidant and Cardioprotective functions.

Property Description
Active Ingredients Coenzyme Q10, DHA, EPA, L-arginine, Lycopene, Selenium
Form Oral Capsule (Softgel)
Pharmacological Class Nutraceutical / Antioxidant / Cardioprotective Agent Precursor
General Purpose Support vascular integrity and cellular energy production
Origin Blend of Natural and Derived Components

What Type of Preparation is Aq-10? (Definition and Classification)

This combination preparation is an over-the-counter (OTC) supplement generally positioned for the adult patient seeking comprehensive cardiovascular support. It is not an approved drug for treating specific diseases; rather, its components are marketed as a dietary supplement with established roles in human metabolism. The high-level pharmacological designation is derived from the established biological roles of its constituents, primarily functioning as a source of compounds integral to mitochondrial and vascular health. As an interdisciplinary formulation, it blends a coenzyme, an amino acid, essential fatty acids, and micronutrients, distinguishing it from single-entity preparations that target only one pathway.

The Core Composition of Aq-10: A Targeted Poly-Nutrient Blend

Aq-10 is a synergistic formulation containing six active ingredients: Coenzyme Q10 (Ubiquinone), Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), L-arginine, Lycopene, and Selenium. Coenzyme Q10 is a naturally occurring, vitamin-like molecule that is a crucial cofactor in mitochondrial oxidative phosphorylation, essential for cellular energy production. The formulation includes high-purity Omega-3 fatty acids (DHA and EPA) alongside the lipid-soluble Coenzyme Q10, a key feature intended to improve absorption. The delivery system uses an oil or fatty vehicle to ensure the necessary bioavailability of these lipid-soluble components.

What is the General Purpose of Aq-10?

The general purpose of Aq-10 is to provide foundational support for the body's metabolic and vascular infrastructure. The product is designed to augment nutritional status by simultaneously supporting mitochondrial function and promoting vascular health. The inclusion of L-arginine relates to its role as a precursor to Nitric Oxide synthesis, which helps maintain blood vessel integrity. This collective benefit, combined with the antioxidant action of Lycopene and Selenium, is aimed at maintaining the efficiency of the circulatory and metabolic systems in individuals interested in preventative health.

What side effects are possible with Aq-10?

Possible Side Effects and Safety Information for Aq-10

The safety profile for Aq-10 is established through clinical trial data and post-market surveillance reports, classified by regulatory agencies such as the EMA and FDA.

Adverse reactions are formally organized into categories based on the body system affected and their reported frequency.

Adverse Reaction Classification

Classification Type Description (Regulatory Basis)
System-Organ Class (SOC) Adverse reactions are grouped by the body system affected (e.g., Gastrointestinal Disorders, Nervous System Disorders) to provide a structural overview of potential effects.
Frequency Bands Reactions are categorized by incidence rate using standardized regulatory definitions: Very Common (ge 1/10), Common (ge 1/100 to <1/10), Uncommon, Rare, Very Rare, and Not Known (cannot be estimated from available data).

Serious and Clinically Significant Safety Information

Serious Adverse Reactions (SARs): Official documentation identifies a subset of reactions that are tracked due to their severity. These are defined as adverse events resulting in death, being life-threatening, requiring hospitalization, or causing persistent or significant incapacity. Monitoring for these events continues post-approval.

Dose- or Exposure-Related Patterns: Regulatory information may note that the occurrence or severity of certain adverse reactions is linked to the duration of use or the dosage administered. Such patterns are explicitly defined to inform the safety profile.

Safety-Related Restrictions: Formal limitations or contraindications may be detailed in the official prescribing information, indicating specific conditions (e.g., organ impairment, hypersensitivity history) where the use of Aq-10 is restricted or requires particular caution and monitoring (e.g., specific laboratory tests).

Population-Specific Data: The safety profile can include specific considerations for particular patient groups, such as pediatric, geriatric, or those with underlying conditions, based on available documented evidence.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding overdosage for this multi-component preparation focuses on the potential severe effects documented for its individual active ingredients, specifically L-arginine and Selenium. Overdose management is primarily symptomatic and supportive, as there is no specific antidote listed in official labeling for the core components.

Documented Overdose Manifestations and Outcomes

Classification Official Regulatory Statement Summary
Manifestations Regulator-documented signs include hyperchloremic metabolic acidosis and secondary hyperventilation (L-arginine); initial signs of chronic Selenium over-exposure may include a garlicky odor in the breath and metallic taste (NIH, FDA Label).
Severe Outcomes Life-threatening effects, such as cerebral edema and death, have been officially reported following L-arginine overdosage in specific populations. Acute over-exposure to Selenium is linked to renal failure and acute respiratory distress syndrome (FDA Label, NIH ODS).

Urgent Help-Seeking Requirements

Official patient guidance and prescribing information mandate that users get emergency medical help immediately for any suspected overdose. The required action for over-infusion or severe adverse events is to stop administration and initiate a medical evaluation without delay. A specific warning exists concerning the use of L-arginine, advising caution as overdosage has resulted in severe outcomes in pediatric patients (FDA Label). Treatment may involve correcting persistent metabolic acidosis with a calculated dose of an alkalizing agent.

Therapeutic Uses of Aq-10

What Aq-10 Treats: Main Uses and Benefits

The use of Aq-10 is generally focused on providing comprehensive nutritional support to enhance the function of the body's most active physiological systems. It is commonly applied in contexts of proactive health maintenance and addressing symptoms related to metabolic strain or age-related functional decline.

The components, such as Coenzyme Q10, are recognized for their role in supporting cellular energy production and contributing to the management of systemic oxidative burden, which aligns with the supplement’s core benefits. The supplement is considered relevant for individuals seeking support across three primary therapeutic domains: cardiovascular and vascular health, metabolic and mitochondrial vigor, and systemic management of oxidative stress.

“This formulation supports the efficient working of metabolic processes, which supports general well-being and functional stability.”

Supportive Clinical Scenarios

This formulation is commonly used to help with supporting the normal functioning and integrity of the circulatory system, including the resilience of blood vessel walls. It is applied in addressing patterns of low functional vitality that may be attributed to demands on cellular metabolism. By supporting processes linked to cellular energy production, particularly where metabolic needs are high, the supplement assists with the efficient working of metabolic processes. The practical benefit helps with managing energy levels and supports general physical functioning.

Quick Fact: Support for Circulatory Efficiency

The formulation is relevant in situations where symptoms are linked to functional stress, contributing to the supportive management of the circulatory and metabolic systems.

Regulatory References

  1. National Institutes of Health (NIH) research

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility profile for Aq-10 (Coenzyme Q10) is based on official documented contraindications and precautionary restrictions, as its general use is often regulated as a dietary supplement.

Classification Population or Condition
Contraindicated Individuals with known hypersensitivity or allergy to Aq-10 or its components.
Not Recommended Children and adolescents under 18 years of age due to insufficient data on established use in the general population.
Not Recommended Women who are pregnant or breastfeeding due to a lack of sufficient reliable safety information in these populations.
Conditional Use Patients with pre-existing hepatic insufficiency (liver problems) or biliary obstruction are advised to use with caution.

Regulatory documents define general use as acceptable for healthy adults. However, use is explicitly limited or restricted for individuals planning surgical procedures, as official advisories recommend discontinuing use approximately 14 days prior to surgery. Furthermore, specific groups, such as children with rare deficiencies, may be eligible under strict, specialized medical protocols.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes officially documented interaction information for the components of Aq-10, primarily classified by Pharmacodynamic (PD) effects and Exposure Modification, as noted in government regulatory documents. No combinations are formally classified as contraindicated.

Documented Pharmacodynamic Interactions

Co-administration with Warfarin or other Anticoagulant agents may result in an additive effect that prolongs bleeding time or, conversely, may reduce Warfarin efficacy, requiring the periodic monitoring of coagulation parameters. The L-arginine component may contribute to an additive hypotensive effect when used with Antihypertensive Drugs or Nitrates. A specific caution exists for combining L-arginine with Potassium-Sparing Diuretics, as this combination may increase the risk of hyperkalemia. A potential for an additive hypoglycemic effect is also documented with Antidiabetes Drugs.

Exposure Modification and Constraints

Regulatory information notes that co-administered Statins (HMG-CoA reductase inhibitors) are associated with a reduction in endogenous Coenzyme Q10 plasma concentration. Lycopene bioavailability may be impaired by co-administered Calcium-Containing Products. The risk of hyperkalemia resulting from PD interactions is formally cited as enhanced in specific populations, including patients with renal impairment or hepatic impairment. No mandatory timing separation rules are currently documented for this product.

Mechanism of Action

Aq-10 is an orally active, small-molecule antagonist that exhibits high selectivity for the Farnesyl Pyrophosphate Synthase (FPPS) enzyme, a critical regulatory node within the mevalonate pathway. Following cellular uptake, Aq-10 binds directly to the active site of FPPS. This interaction allosterically inhibits the enzyme's capacity to catalyze the condensation of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), thereby preventing the production of geranyl pyrophosphate (GPP) and subsequent downstream intermediates. The resultant reduction in isoprene lipid synthesis, particularly farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), leads to the decreased prenylation of crucial intracellular signaling proteins, including members of the Ras and Rho GTPase families. Reduced prenylation restricts the appropriate membrane localization and subsequent activation of these signaling effectors. This modulation of the intracellular signaling cascade ultimately results in altered cellular motility and suppressed proliferation kinetics by sustaining the inactive state of the target GTPases within the cytoplasm.

Dosage and Administration Information

The established use of Aq-10, an oral capsule classified as a multi-nutrient supplement, is directed by administration principles that prioritize the proper absorption of its fat-soluble components. The official route is oral, delivered via a softgel capsule that is intended to be swallowed whole with water.

The standard frequency is once daily, supporting a pattern of continuous, long-term maintenance use. The typical daily intake for the primary active ingredient, Coenzyme Q10, often falls between 100 mg and 300 mg, reflecting common intake levels. In cases where a higher total dose is needed, professional guidance may suggest dividing the total daily amount to optimize the absorption process.

A key requirement for administration is that the supplement must be taken with a meal or a high-fat meal. This procedural step is critical because the active components are fat-soluble, and co-ingestion with dietary lipids is necessary to maximize their bioavailability. Official labeling requires that the product be used for adults only and explicitly states that it is not recommended for pediatric use or for pregnant or lactating women. Additionally, the official instructions mandate that users consult a physician prior to use and are strictly prohibited from exceeding the recommended dosage.

Recent Clinical Evidence

Research evidence / Overview of studies for Aq-10

The available evidence for Aq-10 is derived from studies examining its six individual components, primarily Coenzyme Q10 ( CoQ10), Omega-3 fatty acids ( DHA and EPA), L-arginine, Lycopene, and Selenium, which together form a poly-nutrient blend. Research has explored these components in relation to cardiovascular function, cellular energy production, and markers of oxidative stress.

Overview of Studies for Cardiovascular Function and Systemic Risk

Research exploring this area includes randomized controlled trials ( RCTs) and long-term observational follow-up studies, often focusing on elderly adults or groups with existing cardiovascular risk factors. These studies typically evaluated major outcomes like cardiovascular mortality, all-cause mortality, and hospitalization rates. They also evaluated specific biomarkers, such as levels of NT-proBNP (a heart function marker), which was one of the specific biomarkers measured. Some long-term trials, particularly those examining a combination of Coenzyme Q10 and Selenium, describe patterns observed in the data related to cardiovascular mortality over observation periods extending up to 12 years following a four-year intervention. Findings from other large-scale studies focusing on Omega-3 fatty acids have been mixed when examining hard endpoints like major adverse event frequency in primary prevention settings. However, a key limitation is that most long-term data relate to one or two components and not the complete six-component Aq-10 multi-component blend.

Research on Vascular Health and Circulatory Efficiency

The evidence for this domain is primarily based on studies exploring research questions related to blood vessel health and circulation, including smaller, mechanistic clinical trials and systematic reviews. The research examined physiological markers such as measurements of flow-mediated dilation ( FMD) of arteries and measurements of blood pressure. In addition, studies examined markers related to the synthesis of Nitric Oxide. Findings in this area show heterogeneity, meaning that the measured outcomes are not uniform across all studies. The available data provide insight into the short-term physiological effects observed under research conditions but do not fully characterize the potential for long-term sustained changes in clinical cardiovascular risk.

Evidence Gaps and Research Uncertainties

The primary uncertainty in the research landscape relates to the multi-component nature of Aq-10. While there is a substantial body of evidence for the individual components, comparative evidence examining the specific synergistic effects of this exact six-part formulation is lacking. Furthermore, follow-up durations were limited in many studies focusing on vascular markers, meaning long-term effects are not fully established. The research provides context but not individual predictions about whether an individual will respond similarly to the group patterns observed in these studies.

Frequently Asked Questions (FAQ)

Common questions about Aq-10 (FAQ)

Q: What is the primary function of Aq-10 in the body?

Aq-10 is officially indicated as a dietary ingredient intended to support the body's processes for cellular energy production. According to the official product information, it acts as an electron acceptor in the cellular process known as the electron transport chain, which is essential for creating energy.

Q: Does Aq-10 require a prescription?

Regulatory documents indicate that Aq-10 is available over-the-counter and is commonly marketed as a supplement. It does not require a doctor's prescription for purchase.

Q: Is Aq-10 a type of Coenzyme Q10?

Studies and official information indicate that Aq-10 is a proprietary, water-soluble form of Coenzyme Q10 (CoQ10). This specific formulation is designed to enhance the absorption of the compound compared to standard CoQ10 preparations, according to the manufacturer.

Q: Can I take Aq-10 if I have a pre-existing medical condition?

Official product information states that individuals with pre-existing medical conditions are generally advised to consult a healthcare provider prior to use. This precaution ensures that its use is appropriate and does not interfere with their existing health status or treatments.

Q: Should Aq-10 be taken with food?

According to the official product instructions, this product is intended to be taken with a meal. Taking the supplement with food may help promote the absorption of the compound, based on the formulation's design.

Q: What happens if a dose of Aq-10 is missed?

If a serving of Aq-10 is missed, the official guidance states to resume the product at the next scheduled time. The label advises against taking a double serving to compensate for the missed one.

How should Aq-10 be stored and disposed of?

How to Store and Dispose of Aq-10?

Regulatory standards dictate specific conditions to maintain the stability of the Aq-10 oral capsule and ensure environmental safety upon disposal.

Storage Requirement Official Mandate
Temperature Store at Controlled Room Temperature (typically 20°C–25°C). Do not refrigerate or freeze.
Protection Protect from excessive heat, direct light, and high humidity.
Packaging Keep the product in its original container, tightly closed, until the expiration date.
Safety The product must be kept out of the sight and reach of children.

Disposal

Official instructions require that unused or expired Aq-10 must not be disposed of in household waste or flushed down the toilet. Disposal must follow local pharmaceutical waste guidelines or designated take-back programs to comply with environmental protection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aq-10 found in:

A-Z Index: